You are visiting us from Virginia. You are located in HHS Region 3. Your Center is Central East ATTC.

The Impact of Fentanyl on Opioid Addiction and Its Treatment: A Few Observations


Fentanyl has presented an ongoing crisis for the United States.

This webinar will cover the following topics as it relates to this crisis.

  1. How fentanyl has impacted known treatment strategies
  2. Increased opioid overdose deaths
  3. Extended the time required to complete detoxification
  4. Association with precipitated withdrawal when starting buprenorphine
  5. Difficulty to start extended-release injectable (naltrexone) treatment
  6. What's Next?

Learning Objectives 

  • What can we do about fentanyl use in detox protocols?
  • What do we know about fentanyl and BMI index?
  • What do we do with patients who want VIVITROL?
  • What do we do with patients who want SUBOXONE?
  • Next Steps in Treatment Strategies



George Woody, M.D., was a general medical officer in the Navy (1965-1967) and a resident in Psychiatry at Temple University Hospital (1967-1970). He joined Dr. Charles O’Brien at the University of Pennsylvania and the Philadelphia VA Medical Center Drug Dependence Treatment Unit in 1971 and became involved in studies focusing on medical and psychosocial treatments and the relationship between treatment participation and the spread of HIV. He was a member of the FDA Drug Abuse Advisory Committee; DSM-IV Work Group; a Principal Investigator of several treatment studies; participates in NIDA study sections; received a NIDA Senior Scientist award; completed research studies in Brazil, Russia, Ukraine, the Republic of Georgia, Iceland, and Indonesia; and authored or co-authored more than 300 publications including the impact of extended-release injectable naltrexone. He reviews papers for a variety of journals, is a founding member of the Board of Addiction Psychiatry of the American Psychiatric Association, and is co-author of recent guidelines on the treatment of patients with opioid use disorders. He is a member of the American College of Neuropsychopharmacology, a Life Fellow of the American Psychiatric Association, a Doctor Sui Causa at Pavlov State Medical University in St. Petersburg, Russia, a recipient of an award for Medical Education and Research in Substance Abuse, and was a co-awardee of the 2016 Prix Galen Award for contributions to treatment and HIV prevention among underserved populations in Russia.


Sabrina Poole headshotSabrina Poole has 30+ years of experience in the addiction psychology field. She has directed numerous studies for the Center on the Studies of Addiction and the Treatment Research Center of Philadelphia and offers application support for the Addiction Severity Assessment and ASAM Criteria. She is a graduate of State University College at Buffalo and has a Psy.D. Degree in Clinical Psychology. She is an expert in the development and management of study protocols, client recruitment and assessment, and outcomes measurement, which includes study start-up, Institutional Review Board (IRB) submissions, and FDA Investigational New Drug (IND) application support. She is also proficient in project staffing and liaison between local and national grantors (e.g., local city boards and National Institute on Drug Abuse).

Starts: Dec. 14, 2022 11:00 am
Ends: Dec. 14, 2022 12:00 pm
Registration Deadline
December 14, 2022
Event Type
Webinar/Virtual Training
Hosted by
Contact Us for More Info